| Source: TCGA |
| Type: Proapototic |
| TP53 is the most commonly mutated gene in human cancer. TP53 is a gene that encodes for the p53 tumor suppressor protein ; TP73 (Chr.1p36.33) and TP63 (Chr.3q28) genes that encode transcription factors p73 and p63, respectively, are TP53 homologous structures. p53 is a crucial tumor suppressor protein that plays a significant role in regulating the cell cycle, maintaining genomic stability, and preventing tumor formation. It is often referred to as the "guardian of the genome" due to its role in protecting cells from DNA damage and stress. TP53 gene, which encodes the p53 protein, is one of the most frequently mutated genes in human cancers. Overexpression of MDM2, an inhibitor of p53, can lead to decreased p53 activity even in the presence of wild-type p53. In some cancers, particularly those with mutant p53, there may be an overexpression of the p53 protein. Cancers with overexpression: Breast, lung, colorectal, overian, head and neck, Esophageal, bladder, pancreatic, and liver. |
| 6819- | EMD, | Recent advances in the therapeutic potential of emodin for human health |
| - | Review, | Nor, | NA |
| 6829- | EMD, | Molecular Mechanisms of Action of Emodin: As an Anti-Cardiovascular Disease Drug |
| 6836- | EMD, | Emodin and the Anthraquinone Scaffold: Therapeutic Promise and Strategies to Overcome Translational Barriers |
| - | Review, | Nor, | NA |
| 6576- | EU, | Eurycomanone induce apoptosis in HepG2 cells via up-regulation of p53 |
| - | in-vitro, | HCC, | HepG2 |
| 6587- | EU, | Eurycoma longifolia, A Potential Phytomedicine for the Treatment of Cancer: Evidence of p53-mediated Apoptosis in Cancerous Cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | BC, | MCF7 |
| 6584- | EU, | Eurycoma longifolia: an overview on the pharmacological properties for the treatment of common cancer |
| - | Review, | Var, | NA |
| 6389- | Eug, | Molecular Insights into the Management of Eugenol's Anticancer Action Against Colon Cancer: A Detailed Review |
| - | Review, | Colon, | NA |
| 6385- | Eug, | Anticancer potential of eugenol in hepatocellular carcinoma through modulation of oxidative stress, inflammation, apoptosis, and proliferation mechanisms |
| - | in-vivo, | HCC, | HepG2 |
| 6386- | Eug, | A comprehensive and systematic review on potential anticancer activities of eugenol: From pre-clinical evidence to molecular mechanisms of action |
| - | Review, | Var, | NA |
| 6388- | Eug, | Eugenol’s anti-cancer properties, its modulation of signalling pathways, and cascades across various cancers: A review |
| - | Review, | Var, | NA |
| 6341- | Eug, | A Metabolomic Investigation of Eugenol on Colorectal Cancer Cell Line HT-29 by Modifying the Expression of APC, p53, and KRAS Genes |
| - | NA, | Colon, | HT29 |
| 6325- | Eug, | Anticancer Properties of Eugenol: A Review |
| - | Review, | Var, | NA |
| 6846- | EVO, | Evodiamine Inhibits Colorectal Cancer Growth via RTKs Mediated PI3K/AKT/p53 Signaling Pathway |
| - | in-vitro, | CRC, | HT29 | - | in-vitro, | CRC, | HCT116 |
| 5055- | Ex, | Why exercise has a crucial role in cancer prevention, risk reduction and improved outcomes |
| - | Review, | Var, | NA |
| 7513- | FA, | Anti-proliferative and anti-invasive effects of ferulic acid in TT medullary thyroid cancer cells interacting with URG4/URGCP |
| - | in-vitro, | Thyroid, | NA |
| 7512- | FA, | Ferulic acid decreases cell viability and colony formation while inhibiting migration of MIA PaCa-2 human pancreatic cancer cells in vitro |
| - | in-vitro, | PC, | MIA PaCa-2 |
| 7511- | FA, | The anticancer effects of ferulic acid is associated with induction of cell cycle arrest and autophagy in cervical cancer cells |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Cerv, | CaSki |
| 1654- | FA, | Molecular mechanism of ferulic acid and its derivatives in tumor progression |
| - | Review, | Var, | NA |
| 1655- | FA, | Ferulic acid inhibiting colon cancer cells at different Duke’s stages |
| - | in-vitro, | Colon, | SW480 | - | in-vitro, | Colon, | Caco-2 | - | in-vitro, | Colon, | HCT116 |
| 1656- | FA, | Ferulic Acid: A Natural Phenol That Inhibits Neoplastic Events through Modulation of Oncogenic Signaling |
| - | Review, | Var, | NA |
| 2496- | FBZ, | Impairment of the Ubiquitin-Proteasome Pathway by Methyl N-(6-Phenylsulfanyl-1H-benzimidazol-2-yl)carbamate Leads to a Potent Cytotoxic Effect in Tumor Cells |
| - | in-vitro, | NSCLC, | A549 | - | in-vitro, | NSCLC, | H460 |
| 2495- | FBZ, | Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells |
| - | in-vitro, | Melanoma, | A375 |
| 6862- | FBZ, | Research: The Urgent Need for Clinical Studies to Evaluate the Anti-Tumor Efficacy of Fenbendazole |
| - | Review, | Var, | NA |
| 6853- | FBZ, | Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways |
| - | vitro+vivo, | Lung, | A549 | - | in-vitro, | Lung, | H460 |
| 2852- | FIS, | A comprehensive view on the fisetin impact on colorectal cancer in animal models: Focusing on cellular and molecular mechanisms |
| - | Review, | CRC, | NA |
| 2855- | FIS, | Fisetin Induces Apoptosis Through p53-Mediated Up-Regulation of DR5 Expression in Human Renal Carcinoma Caki Cells |
| - | in-vitro, | RCC, | Caki-1 |
| 2859- | FIS, | The Natural Flavonoid Fisetin Inhibits Cellular Proliferation of Hepatic, Colorectal, and Pancreatic Cancer Cells through Modulation of Multiple Signaling Pathways |
| - | in-vitro, | Liver, | HepG2 | - | NA, | Colon, | Caco-2 |
| 2845- | FIS, | Fisetin: A bioactive phytochemical with potential for cancer prevention and pharmacotherapy |
| - | Review, | Var, | NA |
| 2825- | FIS, | Exploring the molecular targets of dietary flavonoid fisetin in cancer |
| - | Review, | Var, | NA |
| 2828- | FIS, | Fisetin, a Potent Anticancer Flavonol Exhibiting Cytotoxic Activity against Neoplastic Malignant Cells and Cancerous Conditions: A Scoping, Comprehensive Review |
| - | Review, | Var, | NA |
| 2829- | FIS, | Fisetin: An anticancer perspective |
| - | Review, | Var, | NA |
| 2830- | FIS, | Biological effects and mechanisms of fisetin in cancer: a promising anti-cancer agent |
| - | Review, | Var, | NA |
| 2842- | FIS, | Fisetin inhibits cellular proliferation and induces mitochondria-dependent apoptosis in human gastric cancer cells |
| - | in-vitro, | GC, | AGS |
| 2843- | FIS, | Fisetin and Quercetin: Promising Flavonoids with Chemopreventive Potential |
| - | Review, | Var, | NA |
| 2832- | FIS, | Fisetin's Promising Antitumor Effects: Uncovering Mechanisms and Targeting for Future Therapies |
| - | Review, | Var, | NA |
| 6917- | FIS, | Dietary flavonoid fisetin regulates aluminium chloride-induced neuronal apoptosis in cortex and hippocampus of mice brain |
| - | in-vivo, | AD, | NA | - | in-vivo, | Park, | NA |
| 6901- | FIS, | Fisetin induces G2/M phase arrest and caspase-mediated cleavage of p21Cip1 and p27Kip1 leading to apoptosis and tumor growth inhibition in HNSCC |
| - | in-vivo, | HNSCC, | CAL33 |
| 6902- | FIS, | Fisetin, a dietary flavonoid, induces cell cycle arrest and apoptosis through activation of p53 and inhibition of NF-kappa B pathways in bladder cancer cells |
| - | in-vitro, | Bladder, | T24/HTB-9 |
| 6980- | Form, | The potential role of formononetin in cancer treatment: An updated review |
| - | Review, | Var, | NA |
| 6981- | Form, | Formononetin: a review of its source, pharmacology, drug combination, toxicity, derivatives, and drug delivery systems |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | PSA, | NA |
| 6976- | Form, | Study on the Mechanism of Formononetin Against Hepatocellular Carcinoma: Regulating Metabolic Pathways of Ferroptosis and Cell Cycle |
| - | vitro+vivo, | HCC, | HepG2 |
| 997- | GA, | The Inhibitory Mechanisms of Tumor PD-L1 Expression by Natural Bioactive Gallic Acid in Non-Small-Cell Lung Cancer (NSCLC) Cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H292 | - | in-vitro, | Nor, | HUVECs |
| 7048- | GA, | Natural bioactive gallic acid shows potential anticancer effects by inhibiting the proliferation and invasiveness behavior in human embryonic carcinoma cells |
| - | in-vitro, | Var, | NA |
| 7033- | GA, | OL, | Gallic Acid Enhances Olaparib-Induced Cell Death and Attenuates Olaparib Resistance in Human Osteosarcoma U2OS Cell Line |
| - | in-vitro, | OS, | U2OS |
| 1300- | GA, | PacT, | carbop, | Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line |
| - | in-vitro, | BC, | MCF7 |
| 7063- | GamB, | Gambogic acid mediates apoptosis as a p53 inducer through down-regulation of mdm2 in wild-type p53-expressing cancer cells |
| - | vitro+vivo, | Lung, | H1299 |
| 7060- | GamB, | New targets for the antitumor activity of gambogic acid in hematologic malignancies |
| - | Review, | Melanoma, | RPMI-8226 |
| 7059- | GamB, | Gambogic acid inhibits growth, induces apoptosis, and overcomes drug resistance in human colorectal cancer cells |
| - | in-vitro, | CRC, | HCT15 |
| 1959- | GamB, | Gambogic acid induces GSDME dependent pyroptotic signaling pathway via ROS/P53/Mitochondria/Caspase-3 in ovarian cancer cells |
| - | in-vitro, | Ovarian, | NA | - | in-vivo, | NA, | NA |
| 5152- | GamB, | Gambogic Acid as a Candidate for Cancer Therapy: A Review |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:236 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid